Imani Saber, Lv Shuojie, Qian Hongbo, Cui Yulan, Li XiaoYan, Babaeizad Ali, Wang Qingjing
Key Laboratory of Artificial Organs and Computational Medicine of Zhejiang Province, Key Laboratory of Pollution Exposure and Health Intervention of Zhejiang Province, Shulan International Medical College, Zhejiang Shuren University, Hangzhou 310015, Zhejiang, China.
Faculty of Medicine, Semnan University of Medical Sciences, Semnan, Iran.
Biotechnol Adv. 2025 Mar-Apr;79:108492. doi: 10.1016/j.biotechadv.2024.108492. Epub 2024 Dec 3.
The prevalence of multidrug-resistant (MDR) ESKAPE pathogens, including Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, and Pseudomonas aeruginosa, represents a critical global public health challenge. In response, mRNA vaccines offer an adaptable and scalable platform for immunotherapy against ESKAPE pathogens by encoding specific antigens that stimulate B-cell-driven antibody production and CD8 T-cell-mediated cytotoxicity, effectively neutralizing these pathogens and combating resistance. This review examines recent advancements and ongoing challenges in the development of mRNA vaccines targeting MDR ESKAPE pathogens. We explore antigen selection, the nuances of mRNA vaccine technology, and the complex interactions between bacterial infections and antibiotic resistance. By assessing the potential efficacy of mRNA vaccines and addressing key barriers to their paraclinical implementation, this review highlights the promising function of mRNA-based immunization in combating MDR ESKAPE pathogens.
多重耐药（MDR）的ESKAPE病原体，包括粪肠球菌、金黄色葡萄球菌、肺炎克雷伯菌、鲍曼不动杆菌和铜绿假单胞菌，其流行是一项严峻的全球公共卫生挑战。作为应对措施，信使核糖核酸（mRNA）疫苗通过编码特定抗原提供了一个可适应且可扩展的免疫治疗平台，这些抗原可刺激B细胞驱动的抗体产生和CD8 T细胞介导的细胞毒性，有效中和这些病原体并对抗耐药性。本综述探讨了针对多重耐药ESKAPE病原体的mRNA疫苗开发的最新进展和持续挑战。我们研究了抗原选择、mRNA疫苗技术的细微差别以及细菌感染与抗生素耐药性之间的复杂相互作用。通过评估mRNA疫苗的潜在疗效并解决其临床前应用的关键障碍，本综述强调了基于mRNA的免疫接种在对抗多重耐药ESKAPE病原体方面的前景。
